- Home
- EXEL vs PEN Comparison
EXEL vs PEN Comparison
Compare EXEL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | PEN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 12.2B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EXEL | PEN |
|---|---|---|
| Price | $43.88 | $312.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 15 |
| Target Price | $45.18 | ★ $329.07 |
| AVG Volume (30 Days) | ★ 2.6M | 451.9K |
| Earning Date | 02-10-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.55 | ★ 367.34 |
| EPS | 2.38 | ★ 4.14 |
| Revenue | ★ $2,288,218,000.00 | $1,333,798,000.00 |
| Revenue This Year | $9.79 | $16.77 |
| Revenue Next Year | $12.01 | $14.12 |
| P/E Ratio | ★ $18.44 | $75.13 |
| Revenue Growth | 9.93 | ★ 14.61 |
| 52 Week Low | $31.90 | $221.26 |
| 52 Week High | $49.62 | $321.38 |
Technical Indicators
Market Signals| Indicator | EXEL | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 59.74 |
| Support Level | $40.83 | $307.00 |
| Resistance Level | $47.24 | $319.78 |
| Average True Range (ATR) | 1.11 | 6.82 |
| MACD | 0.04 | -1.30 |
| Stochastic Oscillator | 48.94 | 43.49 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.